HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus.

Abstract
Therapeutic vaccinations have a potential application in infections where no curative treatment is available. In contrast to HIV, efficacious vaccines for a cat retrovirus, feline leukemia virus (FeLV), are commercially available. However, the infection is still prevalent, and no effective treatment of the infection is known. By vaccinating persistently FeLV-infected cats and presenting FeLV antigens to the immune system of the host, e.g., in the form of recombinant and/or adjuvanted antigens, we intended to shift the balance toward an advantage of the host so that persistent infection could be overcome by the infected cat. Two commercially available FeLV vaccines efficacious in protecting naïve cats from FeLV infection were tested in six experimentally and persistently FeLV-infected cats: first, a canarypox-vectored vaccine, and second, an adjuvanted, recombinant envelope vaccine was repeatedly administered with the aim to stimulate the immune system. No beneficial effects on p27 antigen and plasma viral RNA loads, anti-FeLV antibodies, or life expectancy of the cats were detected. The cats were unable to overcome or decrease viremia. Some cats developed antibodies to FeLV antigens although not protective. Thus, we cannot recommend vaccinating persistently FeLV-infected cats as a means of improving their FeLV status, quality of life or life expectancy. We suggest testing of all cats for FeLV infection prior to FeLV vaccination.
AuthorsA Katrin Helfer-Hungerbuehler, Andrea M Spiri, Barbara Riond, Paula Grest, Felicitas S Boretti, Regina Hofmann-Lehmann
JournalVaccine (Vaccine) Vol. 33 Issue 13 Pg. 1578-85 (Mar 24 2015) ISSN: 1873-2518 [Electronic] Netherlands
PMID25698488 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Ltd. All rights reserved.
Chemical References
  • ALVAC vaccine
  • Antibodies, Viral
  • Gene Products, gag
  • Retroviridae Proteins, Oncogenic
  • Vaccines, Synthetic
  • Viral Vaccines
  • feline leukemia virus protein p27
  • feline leukemia virus vaccine
Topics
  • Animals
  • Antibodies, Viral (immunology)
  • Cat Diseases (therapy, virology)
  • Cats
  • Gene Products, gag (blood)
  • Leukemia Virus, Feline (immunology, pathogenicity)
  • Life Expectancy
  • Quality of Life
  • Retroviridae Infections (therapy, veterinary, virology)
  • Retroviridae Proteins, Oncogenic (administration & dosage, therapeutic use)
  • Tumor Virus Infections (therapy, veterinary, virology)
  • Vaccination (veterinary)
  • Vaccines, Synthetic (administration & dosage, therapeutic use)
  • Viral Load
  • Viral Vaccines (administration & dosage, therapeutic use)
  • Viremia (therapy, veterinary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: